3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
23
Nivolumab
20
atezolizumab
10
Specimen Handling
8
Ipilimumab
8
Cyclophosphamide
8
cabozantinib
6
Magnetic Resonance Spectroscopy
6
fludarabine
5
Sorafenib
5
sargramostim
4
Trastuzumab
4
Sunitinib
4
Bevacizumab
4
lenvatinib
3
enzalutamide
3
durvalumab
3
avelumab
3
X-Rays
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
spartalizumab
2
relatlimab
2
regorafenib
2
palbociclib
2
epacadostat
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Tissue Banks
×
Genitourinary
×
Clear all
NCT06349642
2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
324 enrolled